TRAIL in cancer therapy: present and future challenges
- 2 October 2007
- journal article
- review article
- Published by Informa UK Limited in Emerging Therapeutic Targets
- Vol. 11 (10), 1299-1314
- https://doi.org/10.1517/14728222.11.10.1299
Abstract
Since its identification in 1995, TNF-Related apoptosis-inducing ligand (TRAIL) has sparked growing interest in oncology due to its reported ability to selectively trigger cancer cell death. In contrast to other members of the TNF superfamily, TRAIL administration in vivo is safe. The relative absence of toxic side effects of this naturally occurring cytokine, in addition to its antitumoural properties, has led to its preclinical evaluation. However, despite intensive investigations, little is known in regards to the mechanisms underlying TRAIL selectivity or efficiency. An appropriate understanding of its physiological relevance, and of the mechanisms controlling cancer cells escape from TRAIL-induced cell death, will be required to optimally use the cytokine in clinics. The present review focuses on recent advances in the understanding of TRAIL signal transduction and discusses the existing and future challenges of TRAIL-based cancer therapy development.Keywords
This publication has 155 references indexed in Scilit:
- Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivoBritish Journal of Cancer, 2007
- c-Myc primed mitochondria determine cellular sensitivity to TRAIL-induced apoptosisThe EMBO Journal, 2007
- Generation of a novel proform of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein that can be reactivated by matrix metalloproteinasesExperimental Cell Research, 2006
- Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptorProceedings of the National Academy of Sciences of the United States of America, 2006
- TRAIL promotes metastasis of human pancreatic ductal adenocarcinomaOncogene, 2006
- HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivoBritish Journal of Cancer, 2005
- Deficient Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) Death Receptor Transport to the Cell Surface in Human Colon Cancer Cells Selected for Resistance to TRAIL-induced ApoptosisJournal of Biological Chemistry, 2004
- Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanismsThe Prostate, 2004
- TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-κBOncogene, 2003
- Safety and antitumor activity of recombinant soluble Apo2 ligandJCI Insight, 1999